Results 221 to 230 of about 17,768 (255)
Saprochaete capitata Infection in Teen With Acute Myeloid Leukemia Receiving Echinocandin Prophylaxis. [PDF]
Case Rep Infect DisKillingsworth J +3 more
europepmc +1 more source
Cost-effectiveness of olorofim in the treatment of invasive aspergillosis in patients with limited suitable alternative treatment options: a US payer perspective. [PDF]
Antimicrob Agents ChemotherWalsh TJ +7 more
europepmc +1 more source
Effectiveness and safety of echinocandins combination therapy with the standard of care compared to the standard of care monotherapy for the treatment of invasive aspergillosis infection: a meta-analysis. [PDF]
Front PharmacolAlsowaida YS +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007
The changing pattern in fungal infections has driven the need to expand the targets of antifungal activity. The echinocandins are the newest addition to the arsenal against fungal infections. Three echinocandins have been approved by the United States Food and Drug Administration: caspofungin, micafungin, and anidulafungin.
Diane, Cappelletty +1 more
openaire +2 more sources
The changing pattern in fungal infections has driven the need to expand the targets of antifungal activity. The echinocandins are the newest addition to the arsenal against fungal infections. Three echinocandins have been approved by the United States Food and Drug Administration: caspofungin, micafungin, and anidulafungin.
Diane, Cappelletty +1 more
openaire +2 more sources
Pediatric Infectious Disease Journal, 2011
The echinocandins (ECs), caspofungin (CA), micafungin (MI), anidulafungin (AD), and aminocandin (AM) are the newest class of parenterally administered antifungal agents. This review will discuss their general properties, current indications, and available pediatric data.
Thomas J. Walsh, Jill A. Hoffman
openaire +2 more sources
The echinocandins (ECs), caspofungin (CA), micafungin (MI), anidulafungin (AD), and aminocandin (AM) are the newest class of parenterally administered antifungal agents. This review will discuss their general properties, current indications, and available pediatric data.
Thomas J. Walsh, Jill A. Hoffman
openaire +2 more sources
Echinocandins: production and applications
Applied Microbiology and Biotechnology, 2013The first echinocandin-type antimycotic (echinocandin B) was discovered in the 1970s. It was followed by the isolation of more than 20 natural echinocandins. These cyclic lipo-hexapeptides are biosynthesized on non-ribosomal peptide synthase complexes by different ascomycota fungi.
Emri, Tamás +3 more
openaire +3 more sources
Micafungin - The newest echinocandin
Drugs of Today, 2009Micafungin is one of three currently FDA-approved echinocandins. It has potent in vitro activity against Candida species including non-albicans Candida and azole-resistant Candida species and has also demonstrated clinical efficacy against deep-seated Candida infections. Additional in vitro data and preliminary clinical efficacy studies suggest that it
Zelalem Temesgen +2 more
openaire +3 more sources